The inactivation and clearance of the tricyclic antidepressant imipramine is dependent on CYP2D6 activity. First, CYP2C19 converts imipramine into the active metabolite desipramine, which is then inactivated by CYP2D6. This retrospective single center study aimed to prove whether CYP2C19 and ample CYP2D6 genotyping (taking into consideration four null alleles and three decreased-activity alleles) could be used to predict imipramine and desipramine plasma concentrations in depressed patients, and whether genotype-based drug dose recommendations might assist in the early management of imipramine pharmacotherapy. In 181 subjects with major depressive disorder, drug doses were recorded, imipramine and desipramine plasma concentrations were monitored and CYP2C19 (*2) and CYP2D6 genotype (*3, *4, *5, *6, *9, *10, *41 and gene duplication) were obtained, yielding graded allele-specific CYP2D6 patient groups. Desipramine and imipramine þ desipramine plasma concentration per drug dose unit, imipramine dose at steady state, and imipramine dose requirement significantly depended on CYP2D6 genotype (Kruskal-Wallis test, P < 0.0001). Mean (7s.d.) drug dose requirements were 131 (7109), 155 (770), 217 (795), 245 (7125), 326 (7213), and 509 (7292) mg imipramine/day in carriers of 0, 0.5, 1, 1.5, 2, and > 2 active CYP2D6 genes, respectively. Our protocol for CYP2D6 genotyping will thus importantly aid in the prediction of imipramine metabolism, allowing for the use of an adjusted starting dose and faster achievement of predefined imipramine þ desipramine plasma levels in all genetic patient subgroups. Therefore, therapeutic efficacy and efficiency may be improved, the number of adverse drug reactions decreased, and hospital stay reduced.
Introduction
Worldwide, over 340 million people are affected by major depression. 1 Pharmacotherapy using tricyclic antidepressants such as imipramine, clomipramine, amitriptyline and nortriptyline 2 has been the cornerstone of antidepressive treatment for more than 30 years. 3 Tricyclic antidepressants have a narrow therapeutic window, yet a 50-fold variation in plasma levels is found when they are administered in standard doses. 4 Whereas increased plasma concentrations are associated with substantial toxicity leading to serious side effects, concentrations below the therapeutic range may lead to suboptimal antidepressive treatment or therapy failure. 5, 6 In daily practice, patients are only treated optimally when pharmacotherapy is guided by therapeutic drug monitoring. Dosing of tricyclic antidepressants without such monitoring will fail to result in adequate antidepressant blood levels in 30-50% of patients. 7 The typical tricyclic antidepressant imipramine (IMI) is metabolized by cytochrome P450 (CYP) enzymes. In its major metabolic pathway, IMI is converted into the active metabolite desipramine (DESI) via N-demethylation by CYP2C19. 8 DESI is then hydroxylated by CYP2D6, yielding inactive 2-hydroxy desipramine. 4, 8, 9 Because DESI is an active compound by itself, the sum of the plasma concentrations of parent IMI and primary metabolite DESI is generally used to guide IMI therapy. 10 The CYP2C19 and CYP2D6 genes are highly polymorphic, which leads to enzymatic activities ranging from completely absent (two defective alleles), via normal (two active alleles) to distinctly increased (more than two active alleles). Based on their metabolic activity towards enzyme-specific test compounds, individuals have been classified as poor metabolizers (1-6% of the Caucasian population for CYP2C19 and 5-10% for CYP2D6), intermediate metabolizers, extensive metabolizers or ultrarapid metabolizers (for CYP2D6 only, correlated with inheritance of CYP2D6 gene duplication; present in 1-7% of Caucasians). [11] [12] [13] [14] [15] [16] [17] Adverse drug effects are expected to occur more frequently in poor metabolizers, whereas the group of ultrarapid metabolizers may be prone to therapeutic failure. 6, [18] [19] [20] Until recently, genotyping tests did not allow an adequate prediction of the metabolic capacity of the large subgroups of patients with impaired yet residual CYP2D6 function (intermediate metabolizers; 5-15% of Caucasians). 13 Therefore, a clear-cut gene-dose effect could not be established so far. 3, 21 Newly identified genetic polymorphisms, encoding decreased rather than deficient alleles, such as CYP2D6*41 (which was reported to account for 60% of intermediate metabolizers), 22 may facilitate a greatly desired prediction of metabolic activity and/ or clinical outcome. So far, the potential benefit of pretherapeutic CYP2D6 genotyping has seriously been restricted to a limited fraction of patients, that is, poor and ultrarapid metabolizers only. 3, 23 Recently, graded allele-specific changes in function referred to as semiquantitative functional gene doses (SGDs), taking into account decreased-activity alleles, 17 were introduced to predict amitriptyline and nortriptyline plasma concentrations within the groups of CYP2D6 intermediate and extensive metabolizers in 50 depressed inpatients. 3 In the present study, we assessed the principal CYP2C19 variant allele *2 (accounting for 70% of Caucasian poor metabolizers) 24, 25 along with the CYP2D6 null alleles *3, *4, *5 and *6, the CYP2D6 decreased-activity alleles *9, *10 and *41, and CYP2D6 gene duplication in a large group (n = 181) of depressed patients treated with IMI. Based on the resulting genotyping data, we calculated the corresponding CYP2D6 SGDs and compared these to IMI and DESI plasma levels, and to IMI dose at steady state.
Materials and methods

Patients
The study was conducted as a retrospective single center study at the Department of Psychiatry of the Erasmus MC in Rotterdam, The Netherlands. The protocol was approved by the Ethics Committee of the Erasmus MC and carried out according to the principles of the Declaration of Helsinki. Patients were informed of the aims and design of the study and provided written consent. Both inpatient and outpatient subjects treated with IMI between July 1991 and October 2004 were enrolled in the study. The inclusion criteria were: age 18-65 years, a DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) diagnosis of depressive disorder and a score of 17 or higher on the Hamilton Rating Scale for Depression. 26 Exclusion criteria were: schizophrenia, bipolar or schizo-affective disorder, organic brain syndrome, chronic alcohol or drug abuse, relevant somatic illness, presence of absolute contraindications for IMI, refractoriness to IMI treatment with an adequate plasma level during a previous episode, or pregnancy. Of the 199 patients with major depressive disorder who were eligible, 95% gave informed consent; nine patients were excluded from the analysis because of co-medication interfering with CYP2C19 or CYP2D6 activity; 27 for seven patients, no steady-state data could be obtained. The final analysis included 181 psychiatric patients aged between 18 and 65 years: 55% women and 45% men; 127 inpatients and 54 outpatients. Mean (7s.d.) body weight was 66.3 (711.6) kg for 80 women, and 79.1 (711.4) kg for 71 men. Ethnicity was not explicitly recorded, yet the vast majority of patients were of Caucasian origin. At the time of treatment, genotypes were unknown to the physician. IMI and DESI plasma concentrations were available to guide IMI therapy and to warrant that no potentially toxic concentrations would persist.
Study medication IMI (Tofranil, Ciba-Geigy BV, Arnhem, The Netherlands) was administered orally once daily at 2200 hours, at a dose of 25-900 mg/day. Treatment was started with 75 mg IMI for 2 days, followed by 150 mg IMI for 5 days, and a gradual further increase in dose where necessary. Inpatients generally took their medication under supervision to decrease noncompliance. IMI and DESI plasma levels were determined routinely at the pharmaceutical laboratory of the Erasmus MC, and the IMI dose was adjusted based on a predefined IMI þ DESI plasma level of 200-300 mg/l (according to Perry et al. 10 ) until steady state was reached.
Blood sampling and measurement of plasma concentrations Blood samples were obtained from a peripheral vein between 0730 and 0900 hours on the day after medication. IMI and DESI plasma concentrations were measured according to routine procedures using high-performance liquid chromatography with ultraviolet detection at 220 nm. Solid-phase extraction was performed using Bond Elut TCA columns (Varian Inc., Palo Alto, CA, USA). Lower limits of quantification for IMI and DESI were 21 and 7 mg/l, respectively. In the range of 100-300 mg/l, inter-and intra-assay coefficients of variation were less than 5%, and accuracy ranged from 97 to 102%; for both compounds, total recovery was greater than 78% (n = 6). Given the elimination half-life values of 8-20 and 12-76 h for IMI and DESI, respectively, 28 treatment with an unchanged dose of IMI for at least 12 consecutive days was chosen as to define steady state. For each individual patient, a median value of all IMI, DESI and IMI þ DESI plasma levels, all IMI/DESI ratios and all IMI doses at steady state was then obtained. Molar IMI/DESI ratios were calculated using molecular masses of 280.4 and 266.3 g/mol for IMI and DESI, respectively. 29 Because not all patients reached the target IMI þ DESI concentration, IMI doses administered at steady state were normalized for plasma levels achieved in reality, to facilitate an additional comparison between patients. 'IMI dose requirement' was defined as the IMI dose required to achieve a target IMI þ DESI concentration of 250 mg/l: this was calculated for each patient from the median steady-state IMI þ DESI plasma level (in mg/l) and IMI dose (in mg/day) administered at steady state, assuming linear pharmacokinetics.
Genotyping
For each patient, genomic DNA was isolated from 200 ml of EDTA-treated whole blood using a MagNA Pure LC (Roche Diagnostics GmbH, Mannheim, Germany). Genotyping of the CYP2C19 single nucleotide polymorphism 681G > A corresponding to the null allele *2 (accounting for 70% of Caucasian poor metabolizers) 24, 25 was performed by PCR-restriction fragment length polymorphism analysis according to Goldstein and Blaisdell, 30 using primers 5 0 -CAACCA GAGCTTGGCATATTGTATC-3 0 (forward) and 5 0 -CAA TCAATAAAGTCCCGgGGGTT-3 0 (reverse, with an A > G mismatch in lower case to introduce an internal SmaI restriction site in bold), and 35 cycles of 1 min at 941C (denaturation), 1 min at 501C (annealing) and 1 min at 721C (elongation). The 230-bp reaction product was digested with SmaI to obtain fragments of 113, 101 and 16 bp for the CYP2C19*1 allele, or 214 and 16 bp for the *2 variant allele. CYP2D6 polymorphisms À1584C > G (*2), 100C > T (*4, *10), 1707T > del (*6), 1846G > A (*4), 2549A > del (*3), 2613-2615 delAGA (*9) and 2850C > T (*2, *41) were genotyped by PCR-restriction fragment length polymorphism analysis as described previously. 15, 25, [31] [32] [33] [34] For 100C > T, 1707T > del, 2549A > del, 2613-2615delA-GA and 2850C > T, the entire CYP2D6 gene was first amplified by an initial extra-long PCR according to Gaedigk et al. 15 For 2988G > A (*41), a new PCRrestriction fragment length polymorphism assay was developed, based on a recent paper by Raimundo et al. 35 Gene deletion and duplication were tested by conventional PCR as described. 36, 37 CYP2D6 SGDs were assigned according to Steimer et al. 
Statistics
Statistical analyses were performed using GraphPad Prism version 2.01 (GraphPad Software Inc., San Diego, CA, USA) and SPSS version 9.0 (SPSS Inc., Chicago, IL, USA). Data were analysed employing Kruskal-Wallis and Mann-Whitney nonparametric ANOVA to establish possible differences between groups. Where appropriate, reported P-values are twotailed.
Results
Patient group characteristics
The mean values of IMI, DESI and IMI þ DESI plasma levels, molar IMI/DESI ratios, IMI doses at steady state and calculated drug dose requirements are given in Table 1 . Mean CVs for the individual steady-state IMI and DESI plasma concentrations (corresponding to intra-individual variability) were 21 and 23%, respectively.
CYP2C19 and CYP2D6 genotyping For CYP2C19, we identified 3% poor metabolizers, and 25% (of 181 patients) carriers of one null allele (resulting CYP2C19*2 allele frequency: 15%). Patients with defective CYP2C19 alleles generally displayed higher dose-corrected IMI plasma concentrations and IMI/DESI ratios than patients with two functional alleles (Kruskal-Wallis test, P = 0.0076 and P = 0.022, respectively) (see Table 2 ). With respect to the CYP2C19*2 variant allele, there were no significant differences in the DESI plasma concentrations per dose unit, the sum of both active compounds (IMI þ DESI per dose unit), IMI dose at steady state, or IMI dose requirement (Kruskal-Wallis test, P = 0.94, 0.18, 0.081, and 0.15, respectively). For CYP2D6, allele frequencies were 37% (*1), 22% (*2), 1.8% (*3), 18% (*4), 4.2% (*5), 1.2% (*6), 3.3% (*9), 1.8% (*10), and 10% (*41). Fifteen of 181 patients (8.3%) displayed duplication of the CYP2D6 gene. Graded allele-specific changes in CYP2D6 function, referred to as SGD, 3 were determined for each individual: SGD = 1 for each fully functional allele (*1 or *2), 0 for each null allele (*3, *4, *5 or *6), and 0.5 for each decreased-activity allele (*9, *10 or *41). Six CYP2D6 SGD groups were derived: SGD 0 (n = 10, 5.5%), 0.5 (n = 15, 8.3%), 1 (n = 55, 30%), 1.5 (n = 28, 15%), 2 (n = 62, 34%), and > 2 (n = 11, 6.1%). The SGD groups displayed a significant difference in IMI plasma concentration per dose unit (Kruskal-Wallis test, P = 0.041) and highly significant differences in DESI plasma level per dose unit, the IMI/DESI ratio and IMI þ DESI plasma concentration per dose unit (Kruskal-Wallis tests, P < 0.0001) (see Figure 1 ). The mean (7s.d.) IMI dose administered at steady state was 118 (744), 150 (765), 190 (771), 201 (769), 281 (7126), and 309 (7107) mg/day in carriers of 0, 0.5, 1, 1.5, 2, and > 2 active CYP2D6 genes, respectively (see Figure 2 ) (Kruskal-Wallis test, P < 0.0001). Although IMI dosing was guided by traditional therapeutic drug monitoring, 35 patients (19%) showed steady-state IMI þ DESI plasma levels below the predefined range of 200-300 mg/l, 10 and 19 patients (10%) displayed IMI þ DESI levels above this range. Upon correction for those individuals by calculating the mean IMI dose that would have been required to achieve a steady-state target IMI þ DESI plasma concentration of 250 mg/l, mean (7s.d.) IMI doses for the 0, 0.5, 1, 1.5, 2, and > 2 CYP2D6 SGD groups were 131 (7109), 155 (770), 217 (795), 245 (7125), 326 (7213), and 509 (7292) mg/day, respectively (see Figure 3 ) (Kruskal-Wallis test, P < 0.0001). Drug dose requirement was thus 40% (SGD = 0), 48% (SGD = 0.5), 67% (SGD = 1), 75% (SGD = 1.5) and 156% (SGD > 2), as compared to subjects with SGD = 2 (100%).
Dose-corrected DESI and IMI þ DESI plasma levels were significantly lower (Mann-Whitney tests, Pp0.0026 and Pp0.0017, respectively), and IMI dose at steady state and IMI dose requirement were significantly higher (Pp0.0029 and Pp0.0017, respectively) in patients with SGDs of 1, 1.5 or 2 versus patients with SGD = 0. Notably, we also found highly significant differences in DESI and IMI þ DESI concentrations per dose unit, IMI dose at steady state, and IMI dose requirement between the four subgroups of subjects (SGDs 0.5-2) previously classified as intermediate and extensive metabolizers. Taken together, our findings clearly indicate that IMI metabolism is significantly associated with the CYP2D6 SGD, which can, in turn, directly be calculated from genotyping data.
The combined effects of CYP2C19 and CYP2D6 genotypes showed a significant difference in the mean IMI plasma concentrations per dose unit (Kruskal-Wallis test, P = 0.021), DESI and IMI þ DESI plasma concentrations per dose unit, the molar IMI/ DESI ratio, IMI dose and IMI dose requirement (P < 0.0001) (see Table 2 ). IMI þ DESI plasma levels per dose unit showed particularly uniform patterns, with higher values for a low number of functional CYP2C19 alleles and low CYP2D6 SGDs in almost every single row and column, but the effect of the CYP2C19*2 polymorphism was not significant. When all CYP2C19 *2 carriers were excluded from the analysis, DESI and IMI þ DESI plasma level per dose unit, IMI dose at steady state and IMI dose requirement still significantly depended on CYP2D6 SGD (n = 130; Kruskal-Wallis tests, P < 0.0001). In a multivariate linear regression model, including CYP2C19*2 status, CYP2D6 SGD, body weight and sex, CYP2D6 SGD was the only factor that significantly contributed to the prediction of IMI þ DESI plasma concentration per dose unit (P < 0.001, Z 2 = 0.254), IMI dose (mg/day; P < 0.001, Z 2 = 0.306), and IMI dose requirement (P < 0.001, Z 2 = 0.186). The contribution of the CYP2C19*2 polymorphism to the prediction of either the IMI þ DESI plasma level (P = 0.05, Z 2 = 0.026), IMI dose administered at steady state (P = 0.05, Z 2 = 0.027) or drug dose requirement (P = 0.14, Z 2 = 0.015) was not statistically significant. There was no significant contribution of body weight to the prediction of IMI þ DESI plasma concentration (P = 0.18, Z 2 = 0.012), IMI dose at steady state (P = 0.25, Z 2 = 0.009) or IMI dose requirement (P = 0.27, Z 2 = 0.008), nor any such contribution of sex (P = 0.90, Z 2 < 0.001, P = 0.14, Z 2 = 0.015 and P = 0.69, Z 2 = 0.001, respectively).
Discussion
In the present study, DESI and IMI þ DESI steady-state plasma concentration per drug dose unit, IMI dose administered at steady state and calculated IMI dose requirement significantly depended on CYP2D6 SGD in a large group (n = 181) of depressed patients treated with IMI. More specifically, DESI and IMI þ DESI plasma levels, IMI dose and drug dose requirement were significantly lower and higher, respectively, for carriers of two versus no functional CYP2D6 alleles. This is in agreement with previous in vivo findings in a smaller group of IMI-treated depressed patients, where 28 phenotypic extensive metabolizers were compared to two phenotypic poor metabolizers. 38 Remarkably, we also demonstrate highly significant differences in DESI and IMI þ DESI plasma concentrations per dose unit, IMI dose and IMI dose requirement between the four subgroups of patients (SGDs 0.5, 1, 1.5 and 2) previously classified as intermediate (0.5 and 1) and extensive (1.5 and 2) metabolizers. This clearly indicates the importance of genotyping for the reduced-function CYP2D6 alleles *9, *10 and *41. 22, 35, [39] [40] [41] Testing for CYP2D6 *3, *4, *5, *6, *9, *10 and *41, and gene duplication, followed by calculation of the SGD, may thus help to predict IMI metabolism for all subgroups of subjects, allowing for an alternative IMI starting dose to reach predefined IMI þ DESI plasma concentrations more quickly.
Despite the highly significant differences that we found, it is also clear that dose-corrected plasma levels, IMI dose and calculated drug dose requirement display quite some overlap between the different CYP2D6 genotype groups. The interindividual variability in the pharmacokinetics of IMI and DESI is thus not fully explained by the CYP2D6 genotypes as presented here. Therefore, the current practice of therapeutic drug monitoring should, obviously, not be abandoned, as it will still have to be used to examine individual IMI and DESI pharmacokinetics in detail during the course of therapy. Furthermore, an optimal early antidepressant dosing strategy may have to comprise several endogenic and exogenic factors, possibly including age, body composition, concomitant medication, food components and/or smoking habit. 42 With regard to body composition, IMI doses applied by the physician are not generally based on the patient's sex, weight or body surface area. 7, 43 In line with this, there was no significant contribution of body weight or sex to the prediction of IMI þ DESI plasma concentration, IMI dose at steady state or IMI dose requirement in our present multivariate linear regression model. Our findings corroborate a recent report stating that psychiatric patients genotyped homozygous or heterozygous for CYP2C19 and CYP2D6 null alleles (CYP2C19*2, and CYP2D6*3, *4, *5 and *6) were hospitalized for a longer time during treatment with psychotropic medication, as compared with subjects without these alleles. 44 The allele frequencies and prevalence of 'abnormal' CYP2D6 genotypes (that is, without functional alleles or with an elevated number of functional alleles) that we found were in agreement with the figures previously reported for Western populations, 13, 22, 34, 35, 45, 46 and depressed patients in specialized psychiatric hospitals, 47, 48 respectively. Our finding that the number of active CYP2C19 alleles affects steady-state IMI plasma concentration and molar IMI/DESI ratio, but not DESI plasma concentration or, importantly, IMI þ DESI plasma level, IMI dose and drug dose requirement, is consistent with the involvement of CYP2C19 in the conversion of IMI into DESI. Although CYPC19 genotyping may aid in the prediction of IMI metabolism, we found it of little use to guide IMI dosing towards a predefined target IMI þ DESI plasma level in a population with a relatively limited number of CYP2C19*2 carriers. In populations with a higher prevalence of CYP2C19 variant alleles (such as Asians, with a 28% frequency of the *2 allele), 49 CYP2C19 genotyping may, nevertheless, be appropriate, as suggested previously. 50 Moreover, it cannot be ruled out that there might be different effects for parent IMI versus its active metabolite DESI at certain concentrations, especially since it has been demonstrated that DESI has a higher distribution volume, erythrocyte/plasma ratio and case fatality rate than IMI, implying lower therapeutic plasma levels. 51 Although CYP2C19*2 status does not significantly influence the summed concentration of IMI and DESI, CYP2C19 activity might thus still modify clinical outcome by affecting the IMI/DESI ratio.
Prior knowledge of the potential drug metabolism provided by genotyping might predict the outcome at an earlier stage, allowing for appropriate dose adjustments to reduce the number of patients with IMI þ DESI plasma levels outside the predefined therapeutic range during the early stages of treatment, and to avoid initial adverse events or delayed recovery leading to prolonged hospitalization. 9 In our present study, 30% of patients displayed steadystate IMI þ DESI plasma concentrations outside the predefined range of 200-300 mg/l, 10 even though IMI dosing was guided by therapeutic drug monitoring. Thirty-five patients (19%) showed steady-state IMI-DESI plasma levels below the predefined range and 19 patients (10%) displayed IMI þ DESI levels above this range. Whereas only 11 of 181 (6.1%) predicted ultrarapid metabolizers (CYP2D6 SGD > 2) were present in the entire patient group, 5 (14%) of 35 subjects displaying steady-state IMI þ DESI plasma concentrations < 200 mg/l had SGDs > 2. The percentage of patients showing IMI þ DESI steady state levels < 200 mg/l in the SGD > 2 group was thus 45% (5 of 11), versus 19% overall. These numbers implicate that, apparently, there is some hesitation by physicians to adjust to IMI doses outside the normal range. Likewise, the percentage of subjects with SGD < 1 in the entire group was 14% (25 of 181), whereas 32% (6 of 19 patients) showing IMI þ DESI steady-state plasma levels > 300 mg/l had an SGD < 1. The percentage of patients displaying IMI þ DESI concentrations > 300 mg/l in the SGD < 1 group was thus 24% (6 of 25), versus 10% for all subjects. Potentially, knowledge about genotype, and thus predicted phenotype, may provide additional support for the physician to change doses based on therapeutic drug monitoring to reach the therapeutic window, even if this means deviation from normal drug dosing. Even so, therapeutic windows are still controversial for many antidepressants, and the predetermined IMI þ DESI level of 200-300 mg/l is based on regression analysis of plasma levels rather than therapeutic efficacy, which is often difficult to assess.
In a recent report by Kirchheiner et al., 52 CYP2D6-dependent dose recommendations have been discussed based on a previous study performed in 30 patients under IMI therapy: 38 the authors suggested an IMI dose adjustment (from an average 'common' dose of 100 mg/day) of 28, 79, and 131% for poor metabolizers, intermediate metabolizers (equivalent to carriers of only one functional allele or two decreased-activity alleles, corresponding to SGDs 0.5 and 1) and extensive metabolizers, respectively. In our study comprising 181 patients, we demonstrated that CYP2D6 poor metabolizers (SGD = 0) should receive 40% of the dose for an extensive metabolizer with SGD = 2. This corresponds well to the IMI dose adjustment previously suggested 52 (28 of 131% is 37% for a poor metabolizer dose compared to an extensive metabolizer). For intermediate metabolizers, for which the combined SGDs of 0.5 and 1 result in an average dose of 63% in our study, this is lower than the extrapolated 103% (79 of 131%) based on Kirchheiner et al. 52 Obviously, the precise benefit of pharmacogenetic individualisation will have to be supported by future prospective studies of pretherapeutic genotyping, before exact dose recommendations can subsequently be validated. Comparable studies with the second-generation selective serotonin reuptake inhibitor antidepressants metabolized by CYP2D6 (such as paroxetine and venlafaxine) 27 will also be of interest.
In conclusion, the present study clearly shows that CYP2D6 SGDs are associated with steady-state plasma concentrations of IMI plus DESI and, notably, steadystate IMI dose and calculated dose requirement in a large group (n = 181) of depressed patients. We demonstrate that CYP2D6 genotyping for *3, *4, *5, *6, *9, *10, and *41, and gene duplication may be widely used to realize faster dose adjustment and accomplishment of predefined IMI þ DESI plasma levels. This may, in turn, lead to a reduced number of adverse drug reactions and faster recovery and, therefore, shortened hospitalization. Based on our present data we would thus recommend our protocol for CYP2D6 genotyping before the start of IMI pharmacotherapy.
